After approval of thrombolytic therapy in the USA, Canada Europe and many parts of Asia, decisions for wider approval of i.v. t-PA in a three hour time window are still pending. While the individual study basis for i.v. rt-PA is in public domain for quiet a while, there are new aspect of intravenous thrombolysis, on which this presentation will focus. They include
results from combined analysis of 6 rt-PA trials (ATLANTIS A and A, ECASS I and II and NINDS part I and II) the usefulness of MRI assisted patient selection new developments to enhance the efficacy of thrombolytic therapy with focus on new devices and combination therapies Results from recent trials such as DIAS and AbESTT
